Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:4450 |
Name | renal cell carcinoma |
Definition | A renal carcinoma that has_material_basis_in the lining of the proximal convoluted renal tubule of the kidney. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer kidney cancer renal carcinoma renal cell carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Everolimus | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Famitinib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Lenvatinib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Pazopanib | renal cell carcinoma | not applicable | detail... |
VHL negative | STF-62247 | renal cell carcinoma | sensitive | detail... |
Unknown unknown | Tivozanib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | GDC-0349 | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Everolimus + Lenvatinib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Sunitinib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Alpha 2 Interferon + Bevacizumab | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Sorafenib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Dovitinib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Axitinib | renal cell carcinoma | not applicable | detail... |
CDKN2A loss | Palbociclib | renal cell carcinoma | sensitive | detail... |
VHL mutant | Sunitinib | renal cell carcinoma | predicted - sensitive | detail... |
VHL loss | Bevacizumab | renal cell carcinoma | sensitive | detail... |
VHL loss | ELR510444 | renal cell carcinoma | sensitive | detail... |
VHL mutant | Everolimus | renal cell carcinoma | sensitive | detail... |
Unknown unknown | Temsirolimus | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Tivantinib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | GW5074 + Sorafenib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Bevacizumab + Temsirolimus | renal cell carcinoma | not applicable | detail... |
BRAF V600E | Vemurafenib | renal cell carcinoma | predicted - sensitive | detail... |
Unknown unknown | GDC-0980 | renal cell carcinoma | not applicable | detail... |
VHL inact mut | GDC-0980 | renal cell carcinoma | no benefit | detail... |
VHL inact mut | Everolimus | renal cell carcinoma | predicted - sensitive | detail... |
Unknown unknown | GSK2126458 | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Cabozantinib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | AGS-003 + Sunitinib | renal cell carcinoma | no benefit | detail... |
Unknown unknown | Nivolumab | renal cell carcinoma | not applicable | detail... |
FGFR1 over exp | Sorafenib | renal cell carcinoma | not applicable | detail... |
VHL del | Regorafenib | renal cell carcinoma | predicted - sensitive | detail... |
Unknown unknown | AS1409 | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Bevacizumab + Everolimus | renal cell carcinoma | not applicable | detail... |
ARID1A mutant | Bevacizumab + Everolimus | renal cell carcinoma | predicted - sensitive | detail... |
Unknown unknown | 23814 | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Sunitinib + Trametinib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Pazopanib + Trametinib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Sonepcizumab | renal cell carcinoma | not applicable | detail... |
VHL inact mut | Alpha 2 Interferon + Bevacizumab | renal cell carcinoma | predicted - sensitive | detail... |
Unknown unknown | Itraconazole | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Axitinib + Dalantercept | renal cell carcinoma | no benefit | detail... |
Unknown unknown | Everolimus + Telaglenastat | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Abexinostat + Pazopanib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | MK2206 | renal cell carcinoma | no benefit | detail... |
VHL loss | BPTES | renal cell carcinoma | sensitive | detail... |
VHL loss | Telaglenastat | renal cell carcinoma | sensitive | detail... |
VHL loss | Olaparib + Telaglenastat | renal cell carcinoma | sensitive | detail... |
VHL loss | BPTES + Olaparib | renal cell carcinoma | sensitive | detail... |
Unknown unknown | CPI-444 | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Atezolizumab + CPI-444 | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Everolimus + Sunitinib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Ipilimumab + Nivolumab | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Gemcitabine + MU380 | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Bevacizumab + Carotuximab | renal cell carcinoma | no benefit | detail... |
Unknown unknown | Pazopanib + Pembrolizumab | renal cell carcinoma | no benefit | detail... |
VHL mutant | Unspecified VEGFR inhibitor | renal cell carcinoma | no benefit | detail... |
Unknown unknown | Pegilodecakin | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Everolimus + Vorolanib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Axitinib + X4P-001 | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Axitinib + Carotuximab | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Avelumab + Axitinib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | ODM-203 | renal cell carcinoma | not applicable | detail... |
Unknown unknown | AGS16F | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Axitinib + Pembrolizumab | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Toripalimab | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Emibetuzumab + Ramucirumab | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Lenvatinib + Pembrolizumab | renal cell carcinoma | not applicable | detail... |
Unknown unknown | SRF388 | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Pegilodecakin + Pembrolizumab | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Nivolumab + Pegilodecakin | renal cell carcinoma | not applicable | detail... |
ARID1A inact mut | unspecified immune checkpoint inhibitor | renal cell carcinoma | unknown | detail... |
Unknown unknown | Nivolumab + Tivozanib | renal cell carcinoma | not applicable | detail... |
Unknown unknown | Cabozantinib + Nivolumab | renal cell carcinoma | not applicable | detail... |
Unknown unknown | BMS-986178 + Ipilimumab + Nivolumab | renal cell carcinoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00003553 | Phase II | Cyclophosphamide + Fludarabine Cyclosporine Mycophenolate mofetil Methotrexate | Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer | Completed | USA | 0 |
NCT00184015 | Phase Ib/II | Bevacizumab + Bortezomib | Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) | Unknown status | USA | 0 |
NCT00301990 | Phase II | Aldesleukin + Bevacizumab | Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | Unknown status | USA | 0 |
NCT00717587 | Phase II | Sunitinib Girentuximab Motexafin gadolinium | Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer | Unknown status | USA | 0 |
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Recruiting | USA | 0 |
NCT00828919 | Phase I | Axitinib | Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials | Active, not recruiting | USA | 10 |
NCT00923130 | Phase II | Bevacizumab + Ixabepilone | Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer | Completed | USA | 0 |
NCT00923845 | Phase II | Sirolimus Cyclophosphamide + Pentostatin | Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer | Completed | USA | 0 |
NCT01014065 | Phase II | Sunitinib | A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect) | Completed | CAN | 0 |
NCT01026337 | Phase 0 | Sunitinib | Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer | Completed | USA | 0 |
NCT01120249 | Phase III | Everolimus | S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery | Active, not recruiting | USA | 1 |
NCT01164228 | Phase II | Sunitinib Gemcitabine | Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery | Active, not recruiting | USA | 0 |
NCT01221506 | Phase I | Pazopanib | Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC) | Completed | USA | 0 |
NCT01283048 | Phase I | Bevacizumab + Buparlisib | Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma | Completed | USA | 0 |
NCT01307267 | Phase I | Rituximab + Utomilumab Utomilumab | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | Completed | USA | 4 |
NCT01331135 | Phase I | Sirolimus | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | Completed | USA | 0 |
NCT01361113 | Phase II | Pazopanib | Neoadjuvant Pazopanib in Renal Cell Carcinoma | Completed | USA | 0 |
NCT01370109 | Phase I | Sunitinib | Cardiovascular Effects of Sunitinib Therapy (CREST) | Completed | USA | 0 |
NCT01391143 | Phase I | MGA271 | Safety Study of MGA271 in Refractory Cancer | Completed | USA | 0 |
NCT01399918 | Phase II | Bevacizumab + Everolimus | Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) | Completed | USA | 0 |
NCT01480154 | Phase I | Hydroxychloroquine + MK2206 | Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer | Active, not recruiting | USA | 0 |
NCT01510119 | Phase Ib/II | Everolimus + Hydroxychloroquine | Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma | Completed | USA | 0 |
NCT01517243 | Phase II | Temsirolimus Sunitinib | Phase II Study of Alternating Sunitinib and Temsirolimus | Active, not recruiting | USA | 0 |
NCT01575548 | Phase III | Pazopanib | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | Active, not recruiting | USA | 0 |
NCT01582009 | Phase Ib/II | Everolimus + Panobinostat | Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate | Terminated | USA | 0 |
NCT01582672 | Phase III | Sunitinib | Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC) | Terminated | USA | CAN | 6 |
NCT01625936 | Phase I | Bevacizumab CRLX101 | CRLX101 Plus Bevacizumab in Advanced RCC | Completed | USA | 0 |
NCT01649180 | Phase II | Axitinib | NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801) | Terminated | USA | 0 |
NCT01664182 | Phase II | Sunitinib + Trebananib Pazopanib + Trebananib Sorafenib + Trebananib Trebananib Bevacizumab + Trebananib | Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer | Completed | USA | 0 |
NCT01727336 | Phase II | Axitinib + Dalantercept Axitinib | Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma | Completed | USA | 0 |
NCT01730118 | Phase I | HER2 Vaccine | Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing | Completed | USA | 0 |
NCT01767636 | Phase II | Pazopanib | Pazopanib in Treating Patients With Metastatic Non-Clear Cell Kidney Cancer | Active, not recruiting | USA | 0 |
NCT01806064 | Phase I | Bevacizumab + Carotuximab | A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma | Terminated | USA | 3 |
NCT01835158 | Phase II | Cabozantinib Cabozantinib + Sunitinib | Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer | Completed | USA | 0 |
NCT01865747 | Phase III | Everolimus Cabozantinib | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma | Unknown status | USA | CAN | 24 |
NCT01946789 | Phase I | ALT-803 | A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01984242 | Phase II | Atezolizumab Sunitinib Atezolizumab + Bevacizumab + Capecitabine | A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma | Completed | USA | 8 |
NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02013804 | Phase I | MEDI0680 | A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies | Completed | USA | 0 |
NCT02014636 | Phase I | Pazopanib Pembrolizumab | Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC) | Completed | USA | 1 |
NCT02071862 | Phase I | Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | Completed | USA | 0 |
NCT02082210 | Phase Ib/II | Emibetuzumab + Ramucirumab | A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer | Completed | USA | 0 |
NCT02089334 | Phase Ib/II | Everolimus + RX-0201 Everolimus | Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer | Terminated | USA | 0 |
NCT02089685 | Phase Ib/II | Ipilimumab Peginterferon alfa-2b Pembrolizumab | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | Active, not recruiting | 0 | |
NCT02122809 | Phase I | Chiauranib | Phase I Study of Chiauranib in Patients With Advanced Solid Tumors | Completed | 1 | |
NCT02133742 | Phase I | Axitinib + Pembrolizumab | A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer | Completed | USA | 0 |
NCT02164838 | Phase I | Axitinib | VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors | Completed | USA | CAN | 0 |
NCT02170389 | Phase I | AGS-003 | Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer | Terminated | USA | 0 |
NCT02174172 | Phase I | Atezolizumab + Bevacizumab + Peg-interferon alfa-2a Atezolizumab + Interferon alpha-2b Atezolizumab + Peg-interferon alfa-2a Atezolizumab + Ipilimumab Atezolizumab + Obinutuzumab | A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 1 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02187302 | Phase II | Bevacizumab + CRLX101 | CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) | Completed | USA | 1 |
NCT02212730 | Phase I | Pembrolizumab | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) | Terminated | 0 | |
NCT02231749 | Phase III | Ipilimumab + Nivolumab Sunitinib | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) | Active, not recruiting | USA | CAN | 26 |
NCT02273752 | Phase II | Everolimus | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | Terminated | USA | 0 |
NCT02298959 | Phase I | Aflibercept + Pembrolizumab | Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT02404441 | Phase Ib/II | Spartalizumab | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | Completed | USA | CAN | 12 |
NCT02406521 | Phase I | Pazopanib Radium Ra 223 dichloride Sorafenib | Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases | Completed | USA | 0 |
NCT02420821 | Phase III | Bevacizumab Sunitinib Atezolizumab | A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma | Active, not recruiting | USA | CAN | 19 |
NCT02432846 | Phase II | Sunitinib | Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) (MERECA) | Completed | USA | 8 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02471846 | Phase I | GDC-0919 Atezolizumab | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | 3 |
NCT02493751 | Phase I | Avelumab + Axitinib | A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer | Active, not recruiting | USA | 2 |
NCT02495103 | Phase Ib/II | Metformin + Vandetanib | Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma | Terminated | USA | 0 |
NCT02498665 | Phase I | DSP-7888 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Completed | USA | 0 |
NCT02501096 | Phase Ib/II | Pembrolizumab Lenvatinib | Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | Active, not recruiting | USA | 2 |
NCT02543645 | Phase Ib/II | Atezolizumab + Varlilumab | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | Terminated | USA | 0 |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02560012 | Phase II | Everolimus Sorafenib Temsirolimus Axitinib Sunitinib Pazopanib | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | Terminated | USA | 0 |
NCT02576665 | Phase I | Toca 511 + Toca FC | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) | Terminated | USA | 0 |
NCT02596035 | FDA approved | Nivolumab | A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374) | Active, not recruiting | USA | 0 |
NCT02599779 | Phase II | Pembrolizumab | A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients | Recruiting | CAN | 0 |
NCT02608268 | Phase Ib/II | Spartalizumab Sabatolimab | Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Active, not recruiting | USA | CAN | 7 |
NCT02608385 | Phase I | Pembrolizumab | Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02619253 | Phase Ib/II | Pembrolizumab + Vorinostat | Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT02627963 | Phase III | Sorafenib Tivozanib | A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC | Active, not recruiting | USA | CAN | 10 |
NCT02639182 | Phase II | AGS16F Axitinib | A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma | Active, not recruiting | USA | CAN | 0 |
NCT02646319 | Phase I | Nab-Rapamycin | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | Completed | USA | 0 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02650635 | Phase I | Cyclophosphamide + Motolimod + Pegfilgrastim | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | Terminated | USA | 0 |
NCT02655822 | Phase I | Atezolizumab + CPI-444 CPI-444 | Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers | Recruiting | USA | CAN | 1 |
NCT02684006 | Phase III | Avelumab + Axitinib Sunitinib | A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) | Active, not recruiting | USA | CAN | 19 |
NCT02697591 | Phase Ib/II | INCAGN01876 | An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02718066 | Phase Ib/II | Chidamide + Nivolumab | Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT02721732 | Phase II | Pembrolizumab | Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors | Recruiting | USA | 0 |
NCT02724020 | Phase II | MLN1117 + Sapanisertib Sapanisertib Everolimus | MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma | Completed | USA | CAN | 6 |
NCT02724878 | Phase II | Atezolizumab + Bevacizumab + Capecitabine | Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT02729194 | Phase I | Pazopanib | Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma | Completed | USA | 0 |
NCT02762006 | Phase I | Durvalumab + Tremelimumab | Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma | Completed | USA | 0 |
NCT02781506 | Phase II | Nivolumab | Nivolumab and Stereotactic Ablative Radiation Therapy Versus Nivolumab Alone for Metastatic Renal Cancer | Active, not recruiting | USA | 0 |
NCT02795819 | Phase I | AR-42 + Pazopanib | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | Terminated | USA | 0 |
NCT02799095 | Phase I | ALKS 4230 | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | Recruiting | USA | CAN | 4 |
NCT02811861 | Phase III | Everolimus + Lenvatinib Sunitinib Lenvatinib + Pembrolizumab | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma | Active, not recruiting | USA | CAN | 18 |
NCT02835833 | Phase I | Bevacizumab + Nintedanib | Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors | Completed | USA | 0 |
NCT02853331 | Phase III | Axitinib + Pembrolizumab Sunitinib | Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) | Active, not recruiting | 0 | |
NCT02853344 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) | Active, not recruiting | 0 | |
NCT02867592 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Active, not recruiting | USA | 0 |
NCT02915783 | Phase II | Everolimus + Lenvatinib | A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease | Active, not recruiting | USA | 0 |
NCT02923349 | Phase Ib/II | INCAGN01949 | A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 3 |
NCT02923531 | Phase Ib/II | Nivolumab + X4P-001 | Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma | Completed | USA | 0 |
NCT02950766 | Phase I | Ipilimumab + NeoVax | A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT02952248 | Phase I | BI 754091 | A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours | Active, not recruiting | USA | CAN | 1 |
NCT02956798 | Phase II | Pazopanib | Pazopanib Vs. Local Therapy for Renal Cancer With Metastases | Active, not recruiting | USA | 0 |
NCT02962804 | Phase II | Nivolumab | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | Withdrawn | USA | 0 |
NCT02982954 | Phase III | Ipilimumab + Nivolumab | A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920) | Active, not recruiting | USA | 0 |
NCT02983045 | Phase Ib/II | Nivolumab + NKTR-214 | A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02) | Active, not recruiting | USA | CAN | 6 |
NCT02996110 | Phase II | Nivolumab + Relatlimab Ipilimumab + Nivolumab | A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC) | Recruiting | USA | CAN | 4 |
NCT03015740 | Phase Ib/II | MGCD516 + Nivolumab | MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC) | Active, not recruiting | USA | 0 |
NCT03024437 | Phase Ib/II | Atezolizumab + Entinostat Atezolizumab + Bevacizumab + Entinostat Atezolizumab | Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT03024996 | Phase III | Atezolizumab | A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010) | Active, not recruiting | USA | CAN | 26 |
NCT03029780 | Phase II | Ipilimumab + Nivolumab | An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma | Unknown status | USA | 2 |
NCT03055013 | Phase III | Nivolumab | Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER) | Recruiting | USA | CAN | 1 |
NCT03063762 | Phase I | Atezolizumab + Obinutuzumab + RO6874281 Atezolizumab + Bevacizumab + Obinutuzumab + RO6874281 | Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) | Active, not recruiting | USA | CAN | 7 |
NCT03065179 | Phase II | Ipilimumab + Nivolumab | Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients | Active, not recruiting | USA | 0 |
NCT03092856 | Phase II | Axitinib Axitinib + PF-04518600 | Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer | Recruiting | USA | 0 |
NCT03097328 | Phase II | Sapanisertib | Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT03109015 | Phase II | Sunitinib | Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing (ASSET) | Completed | USA | 0 |
NCT03111901 | Phase Ib/II | Aldesleukin + Pembrolizumab | Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer | Withdrawn | USA | 0 |
NCT03115801 | Phase II | Atezolizumab Nivolumab | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers | Active, not recruiting | USA | 0 |
NCT03117309 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT03126331 | Phase II | Nivolumab | Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients | Recruiting | USA | 0 |
NCT03138512 | Phase III | Ipilimumab + Nivolumab | A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914) | Recruiting | USA | CAN | 23 |
NCT03141177 | Phase III | Cabozantinib + Ipilimumab + Nivolumab Sunitinib Cabozantinib + Nivolumab | A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER) | Active, not recruiting | USA | 17 |
NCT03142334 | Phase III | Pembrolizumab | Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) | Active, not recruiting | USA | CAN | 19 |
NCT03149822 | Phase Ib/II | Cabozantinib + Pembrolizumab | Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT03163667 | Phase II | Everolimus + Telaglenastat Everolimus | CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC | Completed | USA | 0 |
NCT03165721 | Phase II | Guadecitabine | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer | Completed | USA | 0 |
NCT03172754 | Phase Ib/II | Axitinib + Nivolumab | Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT03189186 | Phase I | Pembrolizumab | Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas | Withdrawn | USA | 0 |
NCT03200587 | Phase I | Avelumab + Cabozantinib | Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC) | Active, not recruiting | USA | 0 |
NCT03203473 | Phase II | Nivolumab Ipilimumab + Nivolumab | Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) | Active, not recruiting | USA | 0 |
NCT03207347 | Phase II | Niraparib | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | Recruiting | USA | 0 |
NCT03207867 | Phase II | PBF-509 + Spartalizumab | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | Recruiting | USA | 13 |
NCT03239145 | Phase I | Pembrolizumab + Trebananib | Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | Recruiting | USA | 0 |
NCT03241173 | Phase Ib/II | INCAGN01949 + Ipilimumab INCAGN01949 + Nivolumab INCAGN01949 + Ipilimumab + Nivolumab | A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | Completed | USA | 0 |
NCT03260504 | Phase I | Aldesleukin + Pembrolizumab | Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer | Recruiting | USA | 0 |
NCT03260894 | Phase III | Epacadostat + Pembrolizumab Pazopanib + Sunitinib | Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC | Active, not recruiting | USA | CAN | 18 |
NCT03264066 | Phase II | Atezolizumab + Cabozantinib | A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors | Completed | USA | 5 |
NCT03277352 | Phase Ib/II | Epacadostat + INCAGN01876 + Pembrolizumab | INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | Completed | USA | 0 |
NCT03289962 | Phase I | RO7198457 Atezolizumab + RO7198457 | A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Recruiting | USA | CAN | 6 |
NCT03311334 | Phase I | Atezolizumab + DSP-7888 DSP-7888 + Nivolumab | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT03319459 | Phase I | FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT03324373 | Phase II | Everolimus + Lenvatinib | Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) | Recruiting | USA | 0 |
NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03396211 | Phase I | Nivolumab + Rivoceranib | Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer | Active, not recruiting | USA | 0 |
NCT03401788 | Phase II | PT 2977 | A Phase 2 Study of MK-6482 (PT2977) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | Active, not recruiting | USA | 3 |
NCT03428217 | Phase II | Cabozantinib Cabozantinib + Telaglenastat | CB-839 With Cabozantinib vs. Placebo With Cabozantinib in Patients With Metastatic Renal Cell Carcinoma (CANTATA) | Active, not recruiting | USA | 7 |
NCT03435640 | Phase Ib/II | NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 | A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies | Active, not recruiting | USA | 0 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Recruiting | USA | 1 |
NCT03473730 | Phase I | Daratumumab | Daratumumab in Patients With Metastatic Renal Cell Carcinoma (MRCC) or Muscle Invasive Bladder Cancer | Recruiting | USA | 0 |
NCT03474497 | Phase Ib/II | Aldesleukin + Pembrolizumab + Radiotherapy | Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | Recruiting | USA | 0 |
NCT03501381 | Phase II | Entinostat + Interleukin-12 Interleukin-12 | High Dose IL 2 and Entinostat in RCC | Active, not recruiting | USA | 0 |
NCT03502330 | Phase I | APX005M + Cabiralizumab + Nivolumab APX005M + Cabiralizumab | APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT03517488 | Phase I | XmAb20717 | A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) | Recruiting | USA | 0 |
NCT03525795 | Phase Ib/II | CPI-1205 + Ipilimumab | ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03541902 | Phase II | Cabozantinib Sunitinib | Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT03552380 | Phase II | Entinostat + Ipilimumab + Nivolumab | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03562507 | Phase II | CEP-11981 CEP-11981 + Nivolumab | Phase 2 Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT03592472 | Phase III | Pazopanib Abexinostat + Pazopanib | A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) | Active, not recruiting | USA | 4 |
NCT03595124 | Phase II | Nivolumab Axitinib + Nivolumab Axitinib | A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) | Recruiting | USA | 0 |
NCT03598816 | Phase II | Durvalumab + Tremelimumab | PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma | Withdrawn | 0 | |
NCT03608020 | Phase Ib/II | BMX-001 | A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy | Recruiting | USA | 0 |
NCT03621982 | Phase I | Camidanlumab Tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03628677 | Phase I | AB154 AB154 + GLS-010 | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Recruiting | USA | 1 |
NCT03629756 | Phase I | AB928 + GLS-010 | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Active, not recruiting | USA | 1 |
NCT03633110 | Phase Ib/II | GEN-009 GEN-009 + Nivolumab | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | Active, not recruiting | USA | 0 |
NCT03634540 | Phase II | Cabozantinib + PT 2977 | A Trial of PT2977 in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) | Recruiting | USA | 0 |
NCT03635892 | Phase II | Cabozantinib + Nivolumab | A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT03637803 | Phase I | MRx0518 + Pembrolizumab | MRx0518 and Pembrolizumab Combination Study | Recruiting | USA | 0 |
NCT03656718 | Phase Ib/II | Nivolumab + rHuPH20 | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) | Recruiting | USA | 10 |
NCT03679767 | Phase II | Retifanlimab | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | Active, not recruiting | USA | 7 |
NCT03729245 | Phase III | Cabozantinib + Sunitinib Nivolumab + NKTR-214 | A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) | Active, not recruiting | USA | 10 |
NCT03752398 | Phase I | XmAb23104 | A Study of XmAb23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3) | Recruiting | USA | 0 |
NCT03758781 | Phase I | Cyclophosphamide + IRX-2 + Nivolumab | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT03775850 | Phase Ib/II | EDP1503 EDP1503 + Pembrolizumab | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | Recruiting | USA | CAN | 0 |
NCT03786796 | Phase II | Olaparib | Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID) | Recruiting | USA | 0 |
NCT03793166 | Phase III | Nivolumab Cabozantinib + Nivolumab Cabozantinib Ipilimumab + Nivolumab | Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer | Recruiting | USA | 1 |
NCT03798626 | Phase I | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + XOMA 052 Paclitaxel + Ramucirumab + XOMA 052 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + XOMA 052 Cabozantinib + XOMA 052 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | Recruiting | USA | CAN | 15 |
NCT03809624 | Phase I | INBRX-105 | Study of INBRX-105 in Patients With Solid Tumors (PDL1x41BB) | Recruiting | USA | 0 |
NCT03816345 | Phase I | Nivolumab | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | Recruiting | USA | 0 |
NCT03845166 | Phase I | XL092 | A Study of XL092 in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT03849469 | Phase I | Pembrolizumab + XmAb22841 XmAb22841 | A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) | Recruiting | USA | 0 |
NCT03873402 | Phase III | Nivolumab Ipilimumab + Nivolumab | An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | Active, not recruiting | USA | 13 |
NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Recruiting | USA | CAN | 2 |
NCT03905889 | Phase I | Abemaciclib + Sunitinib | A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT03926013 | Phase I | JNJ-63898081 | A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors | Recruiting | USA | CAN | 1 |
NCT03961698 | Phase II | Atezolizumab + Bevacizumab + IPI-549 Atezolizumab + IPI-549 + Nab-paclitaxel | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) (MARIO-3) | Recruiting | USA | 0 |
NCT03977467 | Phase II | Atezolizumab + Carboplatin Atezolizumab + Cisplatin Atezolizumab Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin | Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | Recruiting | USA | 0 |
NCT03991130 | Phase II | Aldesleukin + Nivolumab | High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT04020185 | Phase Ib/II | IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 | Safety and Efficacy Study of IMSA101 in Refractory Malignancies | Recruiting | USA | 0 |
NCT04022343 | Phase II | Cabozantinib | Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer | Recruiting | USA | 0 |
NCT04028245 | Phase I | Canakinumab + Spartalizumab | A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1) | Recruiting | USA | 0 |
NCT04060407 | Phase Ib/II | CD24Fc + Ipilimumab + Nivolumab | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (CINDI) | Not yet recruiting | USA | 0 |
NCT04068831 | Phase II | Avelumab + Talazoparib | Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma | Recruiting | USA | 0 |
NCT04071223 | Phase II | Cabozantinib + Radium Ra 223 dichloride Cabozantinib | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study | Recruiting | USA | 0 |
NCT04074967 | Phase Ib/II | Ipilimumab + Pexmetinib Nivolumab + Pexmetinib | Study of ARRY-614 Plus Either Nivolumab or Ipilimumab | Recruiting | USA | 0 |
NCT04088500 | Phase II | Ipilimumab + Nivolumab | A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma | Recruiting | USA | CAN | 0 |
NCT04090710 | Phase II | Nivolumab Ipilimumab + Nivolumab | SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK) | Recruiting | CAN | 1 |
NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04112498 | Phase I | Nivolumab + Relatlimab + rHuPH20 | A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab | Recruiting | USA | 0 |
NCT04114136 | Phase II | Nivolumab Metformin + Nivolumab Pembrolizumab Metformin + Pembrolizumab Pembrolizumab + Rosiglitazone Nivolumab + Rosiglitazone | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | 0 |
NCT04198766 | Phase I | INBRX-106 INBRX-106 + Pembrolizumab | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Recruiting | USA | 0 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04262375 | Phase II | Durvalumab + Oleclumab | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION (DOMINATION) | Withdrawn | CAN | 0 |
NCT04267120 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial) | Recruiting | USA | 0 |
NCT04311710 | Phase Ib/II | Ipilimumab + Nivolumab Ipilimumab + Nivolumab + rHuPH20 | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U) | Recruiting | USA | 8 |
NCT04322955 | Phase II | Cabozantinib + Nivolumab | CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition (Cyto-KIK) | Recruiting | USA | 0 |
NCT04337970 | Phase Ib/II | Axitinib + Talazoparib | Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer | Recruiting | USA | 0 |
NCT04338269 | Phase III | Cabozantinib Atezolizumab + Cabozantinib | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment (CONTACT-03) | Recruiting | USA | CAN | 13 |
NCT04349267 | Phase Ib/II | BMS-986315 + Cetuximab BMS-986315 BMS-986315 + Nivolumab | Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04370509 | Phase II | Pembrolizumab Axitinib + Pembrolizumab | Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery | Recruiting | USA | 0 |
NCT04393350 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab Before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer | Recruiting | USA | 0 |
NCT04413123 | Phase II | Cabozantinib + Ipilimumab + Nivolumab | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | Recruiting | USA | 0 |
NCT04423029 | Phase Ib/II | DF6002 + Pembrolizumab DF6002 | Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications | Recruiting | USA | 0 |
NCT04429321 | Phase I | Ipilimumab + Nivolumab | Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary | Recruiting | USA | 0 |
NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Recruiting | USA | 0 |
NCT04438083 | Phase I | CTX130 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma | Recruiting | USA | CAN | 2 |
NCT04442126 | Phase Ib/II | NM21-1480 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04489771 | Phase II | PT 2977 | A Study of MK- 6482 in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) | Recruiting | USA | 5 |
NCT04495257 | Phase I | APX005M + Ipilimumab + Nivolumab | A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) | Recruiting | USA | 0 |
NCT04505839 | Phase I | STP1002 | First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors | Recruiting | USA | 0 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Recruiting | USA | 0 |
NCT04521413 | Phase Ib/II | CFI-402411 + Pembrolizumab CFI-402411 | Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies | Recruiting | USA | CAN | 1 |
NCT04522323 | Phase I | Axitinib + MEDI5752 | A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma | Recruiting | USA | 3 |
NCT04540705 | Phase Ib/II | Axitinib + Nivolumab + NKTR-214 Axitinib + Nivolumab | A Study to Evaluate the Triplet Combination of Bempegaldesleukin (Bempeg/NKTR-214) Plus Nivolumab and Axitinib and the Doublet Combination of Nivolumab and Axitinib in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread (PIVOT IO 011) | Recruiting | USA | CAN | 0 |
NCT04572451 | Phase I | BMS-986253 + Nivolumab | Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT04592653 | Phase II | ALKS 4230 + Pembrolizumab | A Study of ALKS 4230 on the Tumor Microenvironment (ARTISTRY-3) | Recruiting | USA | 0 |
NCT04603365 | Phase II | Pamiparib + Temozolomide | Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer | Not yet recruiting | USA | 0 |
NCT04696731 | Phase I | ALLO-647 + Cyclophosphamide + Fludarabine ALLO-316 | Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (TRAVERSE) | Not yet recruiting | USA | 0 |